Cellular Therapy and Hematologic Malignancies
Speaker: Gwynn D. Long, M.D.
Topic: CMV Prophylaxis Study Overview
Date: Tuesday, November 26, 2013
Time: 12:00 p.m. – 1:00 p.m.
Location: CR 7015 North Pavilion
Faculty (Speaker) Disclosure: Gwynn Long has indicated he has the following relationships with industry which are relevant to this activity: Principal Investigator for Chimerix.
Activity Medical Director/Planning Committee Disclosure(s): Dr. Mitchell Horwitz discloses the following personal/financial relationships which are relevant to this activity: Advisory Board Member for Genzyme; Principal Investigator for both Otsuka and Pfizer
Accreditation: The Duke University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The Duke University School of Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)ä. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Unapproved Use Disclosure: Duke School of Medicine requires CME faculty (speakers) to disclose to the attendees: 1) When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and 2) Any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty at this symposium may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
- 1.00 AMA PRA Category 1 Credit(s)™